Profund Advisors LLC trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,724 shares of the company’s stock after selling 1,023 shares during the period. Profund Advisors LLC’s holdings in IDEXX Laboratories were worth $1,208,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of IDXX. Atlantic Trust Group LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $65,381,000. Renaissance Technologies LLC lifted its stake in shares of IDEXX Laboratories by 18.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,879,804 shares of the company’s stock worth $293,964,000 after acquiring an additional 290,004 shares during the last quarter. Carillon Tower Advisers Inc. bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $38,842,000. American Century Companies Inc. lifted its stake in shares of IDEXX Laboratories by 32.3% during the 4th quarter. American Century Companies Inc. now owns 946,391 shares of the company’s stock worth $147,997,000 after acquiring an additional 231,216 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of IDEXX Laboratories by 30.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 955,225 shares of the company’s stock worth $148,527,000 after acquiring an additional 220,818 shares during the last quarter. 87.09% of the stock is owned by institutional investors and hedge funds.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $204.53 on Wednesday. IDEXX Laboratories, Inc. has a one year low of $146.09 and a one year high of $206.49. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. The stock has a market capitalization of $17,803.54, a P/E ratio of 64.67, a P/E/G ratio of 2.51 and a beta of 0.58.
IDXX has been the subject of a number of research analyst reports. Piper Jaffray Companies initiated coverage on IDEXX Laboratories in a research note on Tuesday, January 16th. They set an “overweight” rating and a $200.00 price target for the company. BidaskClub lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Bank of America raised their price target on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Finally, Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Buy” and a consensus price target of $194.00.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 2,160 shares of IDEXX Laboratories stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the sale, the chief executive officer now directly owns 1,077,112 shares of the company’s stock, valued at approximately $179,910,017.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Brian P. Mckeon sold 6,602 shares of IDEXX Laboratories stock in a transaction on Monday, February 5th. The shares were sold at an average price of $181.36, for a total value of $1,197,338.72. Following the sale, the vice president now directly owns 47,040 shares of the company’s stock, valued at $8,531,174.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,736 shares of company stock valued at $16,193,502. 2.77% of the stock is currently owned by corporate insiders.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.